Business
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
Processed 3,177 EsoGuard® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into
About this update from Lucid Diagnostics Inc.
[{"type":"text","content":"Processed 3,177 EsoGuard® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement milestonesConference call and webcast to be held today, May 14, at 8:30 AM EDTNEW YORK, May 14, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) (\"PAVmed\"), today provided a business update for the Company and reported financial results for the first quarter ended March 31, 2026.\n \n \n \n \n \n \n \nConference Call and WebcastThe webcast will take place on Thursday, May 14, 2026, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name \"Lucid Diagnostics Business Update\" to join.Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.Business Highlights \"Securing Medicare coverage remains our most important pending milestone, and our confidence in a positive outcome has not wavered,\" said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. \"We continue to build commercial momentum for EsoGuard by generating consistent demand, progressing our Medicare and VA targeting efforts, and expanding engagement with health systems and commercial payors. Together with our strengthened balance sheet, these initiatives have us well-positioned to convert EsoGuard demand to revenue and further accelerate commercialization as Medicare and other key reimbursement milestones are achieved.\"Highlights from the first quarter and recent weeks:Processed 3,177 EsoGuard® Esophageal DNA Tests in 1Q26.Recognized $1.3 million in EsoGuard revenue for 1Q26.Strengthened balance sheet with underwritten public offering of common stock, netting approximately $17 million in proceeds; ended 1Q26 with $45 million in proforma cash, extending runway into 2027.Strong presence at Digestive Disease Week (DDW), which include...